Portfolio AOP Health
Product overview with focus on integrated therapies for rare diseases and in critical care.
Following products are currently available in the UK.
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
Adepend is used as part of a comprehensive programme of treatment against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Argipressin AOP is used to treat diabetes insipidus and bleeding from enlarged veins in the oesophagus.
Esmolol® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
Naloxone hydrochloride is for complete or partial reversal of CNS and especially respiratory depression, caused by natural or synthetic opioids.
Naltrexone AOP is for use as an additional therapy within a comprehensive treatment program including psychological guidance for detoxified patients who have been opioid-dependent.
Tetrabenazine is used for the treatment of diseases causing jerky, irregular, uncontrollable movements (hyperkinetic motor disorders with Huntington’s chorea).
Trepulmix is indicated for the treatment of adult patients with WHO Functional Class (FC) III or IV and - inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or - persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.